Citigroup Inc. Reiterates “Buy” Rating for Puma Biotechnology (PBYI)
Puma Biotechnology (NASDAQ:PBYI)‘s stock had its “buy” rating restated by Citigroup Inc. in a research note issued on Tuesday. They currently have a $99.00 price target on the stock, down from their previous price target of $123.00. Citigroup Inc.’s target price indicates a potential upside of 69.12% from the stock’s previous close.
Shares of Puma Biotechnology (NASDAQ:PBYI) traded up 5.04% on Tuesday, hitting $61.49. The stock had a trading volume of 172,407 shares. Puma Biotechnology has a 52-week low of $33.70 and a 52-week high of $143.65. The stock has a 50-day moving average of $64.76 and a 200-day moving average of $95.37. The company’s market cap is $1.852 billion.
Puma Biotechnology (NASDAQ:PBYI) last released its earnings data on Monday, May 12th. The company reported ($0.67) EPS for the quarter, missing the Thomson Reuters consensus estimate of ($0.48) by $0.19. Analysts expect that Puma Biotechnology will post $-2.56 EPS for the current fiscal year.
Puma Biotechnology, Inc is a development-stage biopharmaceutical company that acquires and develops products for the treatment of various forms of cancer.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.